trial

Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia

NCTId NCT02079844
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 20 (actual)
Sponsored by Takeda
Primary completion 2015-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
20 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2014-03
Primary completion
2015-06
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
RoflumilastSecond generation antipsychotic

Sponsors

TakedaLead Sponsor

Investigators

1
Medical Director Clinical ScienceStudy Director

Sites

0 total

Facts & assertions

4 sourced
Enrollment
20
Phase
PHASE1
Primary Completion Date
2015-06
Status
COMPLETED
relationships
The graph out of here
drug
Roflumilast
drug
Second generation antipsychotic
drug
lead_sponsor
Takeda
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Medical Director Clinical Science
person